2013 | Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia | 문영철 | Article |
2005 | Establishment of effective B lymphocyte ex vivo expansion on human cord blood using TPO, SCF, FL, IL-4, IL-10, and CD40L | 이순남; 성주명; 이경은; 문영철 | Meeting Abstract |
2004 | Establishment of effective B lymphocyte ex vivo expansion on human cord blood using TPO, SCF, FL, IL-4, IL-10, and CD40L. | 이순남; 성주명; 이경은; 문영철 | Meeting Abstract |
2014 | ETV6/RUNX1 Rearrangement Identified by RT-PCR without Evidence on FISH | 정화순; 성주명; 허정원; 문영철 | Article in Press |
2008 | Final Report of "Korean Multicenter AML-2000 Trial": Intention to Treat Analysis Based on Cytogenctics Risk | 문영철 | Meeting Abstract |
2018 | GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms | 이미애; 성주명; 허정원; 조민선; 문영철 | Article |
2003 | Gene expression profile related to prognosis of acute myeloid leukemia | 성주명; 이경은; 문영철 | Meeting Abstract |
2007 | Gene expression profile related to prognosis of acute myeloid leukemia | 성주명; 이경은; 문영철 | Article |
2013 | Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype | 문영철 | Article |
2018 | Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients | 문영철 | Article |
2013 | Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment | 허정원; 문영철 | Article |
2015 | Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression | 정화순; 성주명; 허정원; 문영철 | Article |
2012 | Head-to-Head Comparison of 5-Azacitidine Versus Decitabine for the Treatment of Myelodysplastic Syndrome | 문영철 | Meeting Abstract |
2007 | Hematopoietic stem cells mobilization by G-CSF and LTB4 was significantly suppressed by an oxygen radical scavenger or an inhibitor of NADPH oxidase | 성주명; 유은선; 이경은; 문영철 | Meeting Abstract |
2012 | Hepatitis B Virus Reactivation in Chronic Myeloid Leukemia Treated with Various Tyrosine Kinase Inhibitors: Multicenter, Retrospective Study | 문영철 | Meeting Abstract |
2016 | Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study | 문영철 | Article |
2016 | Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study | 문영철 | Article |
2009 | Immunoglobulin D Multiple Myeloma: Clinical Presentation, Response to Therapy and Prognostic Factors in 75 Patients; An Analysis of the Korean Multiple Myeloma Working Party (KMMWP). | 문영철 | Meeting Abstract |
2011 | Immunoglobulin D multiple myeloma: Response to therapy, survival, and prognostic factors in 75 patients | 문영철 | Article |
2021 | Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma | 문영철 | Article |
2017 | Improved prognostic stratification using NCCN- and GELTAMOinternational prognostic index in patients with diffuse large B-cell lymphoma | 문영철 | Article |
2019 | Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy | 문영철 | Article |
2014 | Incidence of venous thromboembolism following major surgery in Korea: From the Health Insurance Review and Assessment Service database | 문영철 | Article |
2009 | Induction Therapy with "3+7" Chemotherapy Plus ATRA Followed by Consolidations with Three Courses of Idarubicin Alone and Maintenance Therapy with ATRA in Newly Diagnosed Acute Promyelocytic Leukemia (APL) Has An Excellent Leukemia-Free Survival but Minimal Toxicity in Low and Intermediate Risk Groups | 성주명; 문영철 | Meeting Abstract |
2010 | Intensified 1st Cycle Rituximab (R) Plus 8(th) Cycles of R-CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) Chemotherapy In Patients with Advanced or Bulky CD20(+) Diffuse Large B-Cell Lymphoma (DLBCL); Open-Labelled, Multicenter Phase II CISL Study-Interim Analysis. | 문영철 | Meeting Abstract |
2023 | Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study | 문영철 | Article |
2015 | INTERNATIONAL EXTRANODAL NK/T-CELL LYMPHOMA PROJECT: PROGNOSTIC FACTORS IN THE ERA OF NONANTHRACYCLINE-BASED TREATMENT | 문영철 | Meeting Abstract |
2020 | Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis | 문영철 | Article |
2013 | KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement | 문영철 | Article |
2014 | Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients | 문영철 | Article |